Outcome after surgical management of canine insulinoma in 49 cases

Vet Comp Oncol. 2021 Sep;19(3):428-441. doi: 10.1111/vco.12628. Epub 2020 Jul 28.

Abstract

Canine insulinoma has historically been associated with a poor prognosis; however, prolonged survival times have recently been reported. Prognostic indicators that are available preoperatively are of limited predictive accuracy, and consensus on post-operative treatment recommendations is lacking. The objectives of this study were to describe outcomes in dogs with insulinoma treated surgically, and to assess whether selected potential risk factors are strongly associated with outcomes after surgery. Medical records of two institutions were searched for dogs with insulinoma that were treated surgically. Forty-nine dogs were included. Thirty-nine dogs (80%) had immediate resolution of hypoglycaemia and 10 (20%) remained persistently hypoglycaemic postoperatively. The median survival time (MST) for all dogs was 561 days. The MST for dogs that had resolution of hypoglycaemia was 746 days. The median of the overall euglycaemic time (times from surgery to first detection of hypoglycaemia at any time point after surgery) for all dogs was 424 days. Forty-four percent of those that had resolution of hypoglycaemia experienced recurrence of hypoglycaemia by 2 years postoperatively. Pathological stage was a predictor of persistent post-operative hypoglycaemia which, in turn, was a predictor of survival time. These results show that dogs with insulinoma can have prolonged survival, and that pathological stage is a predictor of outcome.

Keywords: insulinoma; metastasis; surgical oncology.

MeSH terms

  • Animals
  • Dog Diseases* / surgery
  • Dogs
  • Hypoglycemia* / veterinary
  • Insulinoma* / surgery
  • Insulinoma* / veterinary
  • Pancreatic Neoplasms* / surgery
  • Pancreatic Neoplasms* / veterinary
  • Prognosis
  • Retrospective Studies
  • Treatment Outcome